XML 18 R3.htm IDEA: XBRL DOCUMENT v3.24.2
Consolidated Income Statements - EUR (€)
€ in Millions, shares in Millions
6 Months Ended 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Profit (loss) [abstract]      
Net sales € 21,209 € 20,187 € 43,070
Other revenues 1,289 1,358 3,374
Cost of sales (6,849) (6,347) (14,236)
Gross profit 15,649 15,198 32,208
Research and development expenses (3,423) (3,193) (6,728)
Selling and general expenses (5,260) (5,182) (10,692)
Other operating income 617 617 1,292
Other operating expenses (2,010) (1,422) (3,516)
Amortization of intangible assets (1,061) (1,035) (2,172)
Impairment of intangible assets 371 (15) (896)
Fair value remeasurement of contingent consideration (66) (26) (93)
Restructuring costs and similar items (1,331) (547) (1,490)
Other gains and losses, and litigation (442) (73) (38)
Operating income 3,044 4,322 7,875
Financial expenses (586) (370) (1,313)
Financial income 281 286 591
Income before tax and investments accounted for using the equity method 2,739 4,238 7,153
Income tax expense (463) (730) (1,602)
Share of profit/(loss) from investments accounted for using the equity method (13) (52) (115)
Net income 2,263 3,456 5,436
Net income attributable to non-controlling interests 17 26 36
Net income attributable to equity holders of Sanofi € 2,246 € 3,430 € 5,400
Average number of shares outstanding (in shares) 1,249.4 1,249.9 1,251.7
Average number of shares after dilution (in shares) 1,253.8 1,254.5 1,256.4
Basic earnings per share (in euros per share) € 1.80 € 2.74 € 4.31
Diluted earnings per share (in euros per share) € 1.79 € 2.73 € 4.30